EAM Investors’s Pliant Therapeutics PLRX Stock Holding History

EAM Investors’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-69,292	Closed	-$1.84M	–	347
2023 Q1	$1.84M	Buy	+69,292	New	+$1.97M	0.36%	130
2022 Q4	–	Sell	-109,220	Closed	-$2.28M	–	322
2022 Q3	$2.28M	Buy	+109,220	New	+$2.09M	0.5%	76

Other funds holding PLRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

EAM Investors's PLRX Position: Q2 2023 in Review

EAM Investors sold out of Pliant Therapeutics (PLRX) in Q2 2023, closing a stake of 69,292 shares — an estimated $1.84M sold.

EAM Investors first reported a position in PLRX in Q3 2022 and held it in 2 quarters. The position peaked at $2.28M in Q3 2022. 144 funds tracked by Wall St. Rank hold PLRX as of Q2 2023.

EAM Investors reported no remaining Pliant Therapeutics position as of Q2 2023 after selling out during the quarter.
EAM Investors sold 69,292 Pliant Therapeutics shares in Q2 2023, an estimated $1.84M.
EAM Investors first reported a position in Pliant Therapeutics in Q3 2022 and held it in 2 quarters.
EAM Investors's Pliant Therapeutics position peaked at $2.28M in Q3 2022.
144 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2023.

Based on EAM Investors's 13F filing for Q2 2023, filed 11 Aug 2023.